Integra LifeSciences (NASDAQ:IART) Stock Gets Price Target Trim from JPMorgan Chase & Co.

Integra LifeSciences (NASDAQ:IART) had its target price reduced by equities researchers at JPMorgan Chase & Co. from $17.00 to $14.00 in a research note issued on Thursday, Benzinga reports. The brokerage currently has an “underweight” rating on the life sciences company’s stock. JPMorgan Chase & Co.’s price target suggests a potential upside of 16.41% from the stock’s previous close.

A number of other brokerages also recently weighed in on IART. Weiss Ratings downgraded Integra LifeSciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, October 2nd. BMO Capital Markets lowered their target price on shares of Integra LifeSciences from $18.00 to $15.00 and set a “market perform” rating on the stock in a research note on Monday, October 5th. UBS Group began coverage on shares of Integra LifeSciences in a research report on Tuesday, July 28th. They set a “neutral” rating and a $19.00 target price for the company. Truist Financial cut their price objective on Integra LifeSciences from $19.00 to $15.00 and set a “hold” rating for the company in a research report on Wednesday, October 14th. Finally, Citigroup reiterated an “outperform” rating on shares of Integra LifeSciences in a report on Thursday. Two equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $16.57.

Integra LifeSciences Price Performance

Shares of Integra LifeSciences stock traded up $0.19 during trading on Thursday, hitting $12.03. The stock had a trading volume of 104,728 shares, compared to its average volume of 908,367. The business has a fifty day moving average of $15.56 and a two-hundred day moving average of $15.56. The firm has a market cap of $935.26 million, a P/E ratio of -133.97, a PEG ratio of 0.71 and a beta of 1.21. The company has a debt-to-equity ratio of 1.75, a current ratio of 3.60 and a quick ratio of 2.11. Integra LifeSciences has a fifty-two week low of $8.70 and a fifty-two week high of $20.49.

Integra LifeSciences (NASDAQ:IART) last issued its earnings results on Wednesday, October 21st. The life sciences company reported $0.59 earnings per share for the quarter, topping analysts’ consensus estimates of $0.56 by $0.03. Integra LifeSciences had a negative net margin of 0.44% and a positive return on equity of 18.30%. The firm had revenue of $411.18 million during the quarter, compared to analysts’ expectations of $413.16 million. During the same period last year, the firm posted ($0.07) earnings per share. On average, sell-side analysts expect that Integra LifeSciences will post 2.39 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Integra LifeSciences

Institutional investors and hedge funds have recently made changes to their positions in the company. Paradigm Capital Management Inc. NY lifted its position in shares of Integra LifeSciences by 50.6% during the first quarter. Paradigm Capital Management Inc. NY now owns 4,012,698 shares of the life sciences company’s stock worth $37,800,000 after purchasing an additional 1,347,700 shares in the last quarter. Wellington Management Group LLP lifted its stake in shares of Integra LifeSciences by 12.4% during the second quarter. Wellington Management Group LLP now owns 1,461,104 shares of the life sciences company’s stock valued at $26,241,000 after acquiring an additional 160,814 shares during the period. Bank of America Corp DE boosted its holdings in Integra LifeSciences by 71.4% in the first quarter. Bank of America Corp DE now owns 1,414,509 shares of the life sciences company’s stock valued at $13,325,000 after acquiring an additional 589,408 shares during the last quarter. Glenmede Trust Co. NA boosted its stake in shares of Integra LifeSciences by 27.4% in the 1st quarter. Glenmede Trust Co. NA now owns 984,686 shares of the life sciences company’s stock valued at $9,276,000 after purchasing an additional 211,774 shares during the last quarter. Finally, Access Investment Management LLC lifted its stake in shares of Integra LifeSciences by 72.0% in the 1st quarter. Access Investment Management LLC now owns 640,535 shares of the life sciences company’s stock valued at $6,034,000 after purchasing an additional 268,085 shares during the period. Institutional investors and hedge funds own 84.78% of the company’s stock.

Integra LifeSciences News Roundup

Here are the key news stories impacting Integra LifeSciences this week:

• Positive Sentiment: Integra reported adjusted EPS of $0.59, above the $0.56 consensus estimate and up from $0.54 a year earlier. GAAP EPS improved to $0.19 from a $0.07 loss, while operating cash flow reached $96 million. Integra LifeSciences Surpasses Q3 Earnings Estimates
• Positive Sentiment: Quarterly revenue rose 2.3% to $411.2 million, supported by 3.9% growth in Specialty Surgery and 6.5% organic growth in Neurosurgery. The company maintained its full-year 2026 revenue guidance of $1.634 billion to $1.654 billion and adjusted EPS guidance of $2.30 to $2.40. Integra Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Integra completed a $2.1 billion refinancing that extends maturities, provides additional covenant flexibility and reduces near-term refinancing risk. Net leverage declined to 3.8x and net debt stood at approximately $1.5 billion. Integra’s Refinancing Merits a Closer Look
• Neutral Sentiment: The refinancing strengthens liquidity, but Integra expects interest expense to rise toward the high end of its previously disclosed 100-to-200-basis-point increase range, potentially limiting earnings upside.
• Negative Sentiment: Fourth-quarter revenue guidance of $413 million to $433 million implies a year-over-year decline of up to 5.2% and missed expectations. The outlook reflects the Cincinnati flood disruption and more cautious assumptions for Tissue Reconstruction. Integra Falls as Tissue Reconstruction Woes Add to Flooding Worries
• Negative Sentiment: Tissue Reconstruction revenue declined 2.2%, adjusted gross margin fell to 61.1% from 62.9%, and the Cincinnati facility disruption reduced quarterly revenue by approximately $7 million.
• Negative Sentiment: Truist lowered its price target from $19 to $15, while a law firm announced an investigation into potential securities-law violations, adding sentiment and litigation risk. Truist Cuts Integra Price Target

About Integra LifeSciences

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, orthopedics and wound care. Its portfolio includes medical devices, surgical instruments and regenerative tissue technologies designed to help healthcare professionals treat complex conditions and support patient recovery.

Integra’s neurosurgical products include dural repair products, cerebrospinal fluid management systems, cranial stabilization devices and specialized surgical instruments.